Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 10/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.58 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.58 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13631383 | 1.00 | PNMT (0.58) | PNMTADRA2AADRA2BADRA2COPRM1 | |
| SCHEMBL25800726 | 0.86 | PNMT (0.58) | PNMTADRA2AADRA2BADRA2COPRM1 | |
| SCHEMBL15854888 | 0.84 | PNMT (0.47) | PNMTADRA2AADRA2BADRA2COPRM1 | |
| SCHEMBL4758601 | 0.84 | PNMT (0.51) | PNMTADRA2AADRA2BADRA2COPRM1 | |
| SCHEMBL31067718 | 0.84 | PNMT (0.47) | PNMTADRA2AADRA2BADRA2COPRM1 | |
| SCHEMBL16233587 | 0.84 | PNMT (0.47) | PNMTADRA2AADRA2BADRA2COPRM1 | |
| SCHEMBL9071241 | 0.84 | PNMT (0.51) | PNMTADRA2AADRA2BADRA2COPRM1 | |
| SCHEMBL10683761 | 0.81 | PNMT (0.49) | PNMTADRA2AADRA2BADRA2COPRM1 | |
| SCHEMBL13227654 | 0.77 | PNMT (0.49) | PNMTADRA2AADRA2BADRA2CKDM1A | |
| SCHEMBL7551539 | 0.77 | PNMT (0.48) | PNMTADRA2AADRA2BADRA2CKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183199-A1 | 2-AMINOINDANE COMPOUNDS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC. (US) | 2023-06-15 | — | — | US | disclosed |
| WO-2022241257-A1 | NAMPT INHBITORS AND USES THEREOF | REMEDY PLAN, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
| US-9453025-B2 | Tricyclic compounds and PBK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-20160219879-A1 | FUNGICIDAL COMPOSITIONS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-08-04 | — | — | US | disclosed |
| US-9326513-B2 | Fungicidal compositions | SYNGENTA PARTICIPATIONS AG (CH) | 2016-05-03 | — | — | US | disclosed |
| US-20150183799-A1 | Tricyclic Compounds and PBK Inhibitors Containing the Same | ONCOTHERAPY SCIENCE INC (JP) | 2015-07-02 | — | — | US | disclosed |
| US-8962648-B2 | Tricyclic compounds and PBK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-02-24 | — | — | US | disclosed |
| US-20140335201-A1 | FUNGICIDAL COMPOSITIONS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-11-13 | — | — | US | disclosed |
| US-20130178459-A1 | TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2013-07-11 | — | — | US | disclosed |
| US-7618969-B2 | Compounds which potentiate glutamate receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2009-11-17 | — | — | US | disclosed |
| US-7572819-B2 | Compounds which potentiate glutamate receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2009-08-11 | — | — | US | disclosed |
| US-20080194648-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED | 2008-08-14 | — | — | US | disclosed |
| US-20070161638-A1 | Compounds which potentiate glutamate receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2007-07-12 | — | — | US | disclosed |
| US-6759103-B2 | NEMATIC, CHOLESTERIC OR CHIRAL SMECTIC LIQUID-CRYSTAL MIXTURES HAVING HIGH ABSOLUTE DIELECTRIC ANISOTROPY VALUES AND WITH A FAVORABLE VISCOSITY/CLEARING POINT RELATIONSHIP; PHOTOSTABILITY; HEAT AND ULTRAVIOLET RADIATION RESISTANCE | CLARIANT FINANCI (BVI) LIMITED (VG) | 2004-07-06 | — | — | US | disclosed |
| US-20030091756-A1 | Nematic, cholesteric or chiral smectic liquid-crystal mixtures having high absolute dielectric anisotropy values and with a favorable viscosity/clearing point relationship; photostability; heat and ultraviolet radiation resistance | CLARIANT INTERNATIONAL LTD. | 2003-05-15 | — | — | US | disclosed |
| US-4738972-A | Hypoglycemic thiazolidinediones | PFIZER INC. (US) | 1988-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161638-A1 | Compounds which potentiate glutamate receptor and uses thereof in medicine | GRM1, GRIN1, HCAR1 | PNMT 2532/4885ADRA2A 577/4885ADRA2B 620/4885 |
| US-20140335201-A1 | FUNGICIDAL COMPOSITIONS | CYP1B1, CYP4B1, DDT | PNMT 2835/4885ADRA2A 2096/4885ADRA2B 967/4885 |
| US-20230183199-A1 | 2-AMINOINDANE COMPOUNDS FOR MENTAL DISORDERS OR ENHANCEMENT | AADAT, SLC1A2, TPH2 | PNMT 4/4885ADRA2A 87/4885ADRA2B 155/4885 |
| US-20130178459-A1 | TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | PBDC1, SBK1, PLK2 | PNMT 3066/4885ADRA2A 4784/4885ADRA2B 4749/4885 |
| US-20080194648-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GRM1, GRIN1, HCAR1 | PNMT 2532/4885ADRA2A 577/4885ADRA2B 620/4885 |
| US-20160219879-A1 | FUNGICIDAL COMPOSITIONS | CYP1B1, CYP4B1, DDT | PNMT 2835/4885ADRA2A 2096/4885ADRA2B 967/4885 |
| US-20150183799-A1 | Tricyclic Compounds and PBK Inhibitors Containing the Same | PBDC1, SBK1, PLK2 | PNMT 3066/4885ADRA2A 4784/4885ADRA2B 4749/4885 |
| US-20030091756-A1 | Nematic, cholesteric or chiral smectic liquid-crystal mixtures having high absolute dielectric anisotropy values and with a favorable viscosity/clearing point relationship; photostability; heat and ultraviolet radiation resistance | SCO2, CNOT1, HCFC1 | PNMT 3043/4885ADRA2A 3398/4885ADRA2B 3475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.